Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies

CPX‐351, a dual‐drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy‐related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia‐related changes. Population pharmacokinetics analy...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Pharmacol
Asıl Yazarlar: Wang, Qi, Banerjee, Kamalika, Vasilinin, Grygoriy, Marier, J.F., Gibbons, Jacqueline A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2018
Konular:
Pharmacometrics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590377/
https://ncbi.nlm.nih.gov/pubmed/30566230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1366
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller